All News

The approval is supported by clinical data from the ATTAIN-1 and ATTAIN-2 trials.

The updated dosing schedule for nusinersen offers increased drug exposure and may further improve outcomes for patients with spinal muscular atrophy.

There was limited evidence supporting additional clinical benefits.

Jonathan Leung, PharmD, RPh, BCPS, discusses the ongoing underutilization of clozapine despite its efficacy, highlighting clinician concerns, lingering perceptions, and the key role pharmacists play in improving its use through education and monitoring.

Fluvoxamine significantly reduced fatigue in adults with long COVID, with a 99% probability of outperforming placebo.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

Explore OTC case studies focused on pain management.

NABP weighs OET and best-section scoring to ease FPGEE path while boosting pass rates and safeguarding patient care.

A FINEARTS-HF subgroup analysis shows patients with HFpEF and comorbid sleep apnea face a 43% higher adjusted cardiovascular risk.

Martinez Sanchez describes early signs of Parkinson disease, how treatment adapts, and how ambulatory pharmacists fine-tune treatment, adherence, and hope amid new therapies.

Experts from NABP and the Arkansas State Board of Pharmacy explain how Pulse by NABP equips pharmacists and regulators with real-time drug supply chain verification tools.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.

Clinical pharmacist specialists emphasized the pharmacist's role closing the gap between guideline recommendations and patient access to CGMs and automated insulin delivery.

Eduardo Martinez Sanchez, PharmD, CPh, BCPS, BCACP, discusses key counseling points, the importance of individualizing disease management, and promising therapies to keep an eye on.

In a phase 2a trial, the oral NLRP3 inhibitor VTX3232 significantly reduced systemic and liver inflammation markers—including hsCRP and IL-6—independent of weight loss, suggesting a promising new approach to lowering cardiovascular risk in patients with obesity.

A phase 3 trial found that the oral PCSK9 inhibitor enlicitide significantly outperformed existing oral therapies in lowering LDL cholesterol.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

Kelly Gable, PharmD, shares how empathy, presence, and practical guidance can transform patient experiences beyond the medication plan.

Learn how NABP’s FPGEC verifies foreign pharmacists and why TOEFL English proficiency standards remain central to US patient safety.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Evolocumab produced a 31% relative risk reduction in major cardiovascular events.

From a pipeline exploding with oral and injectable options to emerging evidence in liver disease, substance use disorder, and kidney disease, Emily Eddy, PharmD, laid out the full scope of incretin therapy's expanding reach at APhA2026.

New data show that pharmacist-led interventions in independent community pharmacies can move the needle on A1C, blood pressure, and stroke risk, even in rural and underserved settings.

SCOUT-HCM trial showed that mavacamten reduced left ventricular outflow tract obstruction in adolescents with obstructive HCM.

The trial's success offers the first robust evidence for targeted pharmacologic intervention in adolescent oHCM.